EDEN PRAIRIE, Minn. & CHARLESTON, W. Va.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq:SRDX) and Paragon Intellectual Properties, LLC announced today the signing of a license agreement under which the companies will collaborate on the development of a novel stent system for the treatment of coronary artery disease. The stent system, which incorporates SurModics’ proprietary FINALE™ Prohealing coating technology and Paragon’s unique low-profile coronary stent system, is designed to address late stent thrombosis, a serious complication occurring in a small percentage of coronary stent cases.
